Viewing Study NCT06269133

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:45 AM
Ignite Modification Date: 2026-02-12 @ 7:10 AM
Study NCT ID: NCT06269133
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-08-27
First Post: 2024-02-13
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients
Sponsor: Regeneron Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Advanced Non-small Cell Lung Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Advanced non-small cell lung cancer (aNSCLC) View
None Epidermal growth factor receptor (EGFR) View
None Anaplastic lymphoma kinase (ALK) View
None C-ros oncogene receptor tyrosine kinase (ROS1) View